Efficacy and safety of Jentadueto® (linagliptin plus metformin)

Expert Opinion on Drug Safety

Volumn 12, Issue 2, 2013, Pages 275-289

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

DPP 4 inhibitor; Fixed dose combination; Linagliptin; Metformin; Pharmacokinetics; Type 2 diabetes mellitus

Indexed keywords

GLIMEPIRIDE; GLUCOSE; LINAGLIPTIN; LINAGLIPTIN PLUS METFORMIN; METFORMIN; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PURINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84874026615     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.771631     Document Type: Article

References (100)

1. Bennett W L, Maruthur N M, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: Bn update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
2. Inzucchi S E, Bergenstal R M, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: B patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
3. Phung O J, Scholle J M, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-18
4. Setter S M, Iltz J L, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: B clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026 (Pubitemid 38096142)
5. Morgan C L, Poole C D, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97:4605-12
6. Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: Drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract SUPPL2007;154:19-28 (Pubitemid 46934643)
7. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-Analysis. BMJ 2012;344:e1369
8. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
9. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127-42 (Pubitemid 350172854)
10. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: B critical review of head-To-head trials. Diabetes Metab 2012;38:89-101
11. Scheen AJ. Controversy about the relative efficacy of DPP-4 inhibitors. Diabetologia 2012;55:2848-9
12. Scheen A J, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet 2012;380:450-2
13. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences. Drugs 2011;71:1441-67
14. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
15. Golightly L K, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14
16. Scheen A J, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410-12
17. Lajara R. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. Expert Opin Pharmacother 2012;13:2663-71
18. Guarino E, Nigi L, Patti A, et al. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13:1377-84
19. Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265-76
20. Chwieduk CM. Sitagliptin/metformin fixed-dose combination: In patients with type 2 diabetes mellitus. Drugs 2011;71:349-61
21. Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmacother 2012;13:139-46
22. Bailey C J, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-33
23. Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68
24. Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol 2011;7:1561-76
25. Scott LJ. Linagliptin: In type 2 diabetes mellitus. Drugs 2011;71:611-24
26. Neumiller J J, Setter SM. Review of linagliptin for the treatment of type 2 diabetes mellitus. Clin Ther 2012;34:993-1005
27. Deeks ED. Linagliptin: B review of its use in the management of type 2 diabetes mellitus. Drugs 2012;72:1793-824
28. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46
29. Mikhail N. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med 2012;124:138-44
30. Lipska K J, Bailey C J, Inzucchi SE. Use of metformin in the setting of mild-To-moderate renal insufficiency. Diabetes Care 2011;34:1431-7
31. Barnett A H, Patel S, Harper R, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: Bn 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab 2012;published on line 2012/09/15; doi: 10.1111/dom.12011
32. Owens D R, Swallow R, Dugi K A, et al. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: B 24-week randomized study. Diabet Med 2011;28:1352-61
33. Agency EM. Jentadueto, INN-linagliptin/metformin HCl. CHMP assessment report. 2012.Available from: Http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Public-assessment-report/human/002279/WC500130972.pdf [Cited published on line
34. Administration FaD. Jentadueto (linagliptin plus metformin). 2012.Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/ 201281s000lbl.pdf [Cited 2012 06/11/2012
35. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71 (Pubitemid 26177181)
36. Graham G G, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98
37. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012;51:411-27
38. Scheen AJ. Linagliptin plus metformin : Pharmacokinetic and pharmacodynamic evaluation. Exp Opin Drug Metab Toxicol 2013;In press
39. Tornio A, Niemi M, Neuvonen P J, et al. Drug interactions with oral antidiabetic agents: Pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 2012;33:312-22
40. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents - An update. Drug Saf 2005;28:601-31 (Pubitemid 41003048)
41. Ishiguro N, Shimizu H, Kishimoto W, et al. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos 2012;41:149-58
42. Graefe-Mody E U, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009;25:1963-72
43. Sambol N C, Brookes L G, Chiang J, et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996;42:510-12 (Pubitemid 26340155)
44. Cuthbertson J, Patterson S, O'Harte FP, et al. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med 2009;26:649-54
45. Graefe-Mody U, Giessmann T, Ring A, et al. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther 2011;33:1096-103
46. Koliaki C, Doupis J. Linagliptin/metformin fixed-dose combination treatment: B dual attack to type 2 diabetes pathophysiology. Adv Ther 2012;29:993-1004
47. Hundal R S, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9
48. Del Prato S, Barnett A H, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: B randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
49. Stumvoll M, Haring H U, Matthaei S. Metformin. Endocr Res 2007;32:39-57 (Pubitemid 351411678)
50. Kirpichnikov D, McFarlane SI, Sowers Jr. Metformin: Bn update. Ann Intern Med 2002;137:25-33
51. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: Bn overview. Clin Sci (Lond) 2012;122:253-70
52. Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 2012;3:10
53. Forst T, Uhlig-Laske B, Ring A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:542-50
54. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94 (Pubitemid 32198418)
55. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004;17:336-42
56. Thondam S K, Cross A, Cuthbertson DJ, et al. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med 2012;29:e205-10
57. Hinke S A, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002;291:1302-8 (Pubitemid 34694333)
58. Mulherin A J, Oh A H, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011;152:4610-19
59. Kappe C, Patrone C, Holst J J, et al. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol 2012;published on line 2012/08/02; doi: 10.1007/s00535-012-0637-5
60. Fadini G P, Albiero M, Menegazzo L, et al. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-Treated patients. Diabetes Obes Metab 2012;14:518-22
61. Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008;4:383-94 (Pubitemid 351711966)
62. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010;27:1409-19
63. Taskinen M R, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: B randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
64. Ross S A, Rafeiro E, Meinicke T, et al. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: B randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 2012;28:1464-75
65. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: B randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-83
66. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: B new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
67. Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: B randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012;14:565-74
68. Haak T. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia. Adv Ther 2012;29:1005-15
69. Schernthaner G, Barnett A H, Emser A, et al. Safety and tolerability of linagliptin: B pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:470-8
70. Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, et al. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: B systematic review and meta-Analysis. Diabetes Obes Metab 2012;14:694-708
71. DeFronzo R A, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9
72. Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011;66:329-31
73. Richard K R, Shelburne J S, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: B review. Clin Ther 2011;33:1609-29
74. Goossen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-Analysis. Diabetes Obes Metab 2012;published on line 2012/04/24; doi: 10.1111/j.1463-1326.2012.01610.x
75. Araki E, Kawamori R, Inagaki N, et al. Long-Term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2012;published on line 2012/11/21; doi: 10.1111/dom.12039
76. Gomis R, Owens D R, Taskinen MR, et al. Long-Term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: Up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract 2012;66:731-40
77. Meloni A R, Deyoung M B, Lowe C, et al. GLP-1 receptor activated insulin secretion from pancreatic beta-cells: Mechanism and glucose dependence. Diabetes Obes Metab 2013;15:15-27
78. Owens D R, Swallow R, Dugi K A, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: B 24-week randomized study. Diabet Med 2011;28:1352-61
79. Drucker D J, Sherman SI, Bergenstal R M, et al. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-31
80. Butler P C, Matveyenko A V, Dry S, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: Innocent bystander or friendly fire? Diabetologia 2010;53:1-6
81. Elashoff M, Matveyenko A V, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
82. Matveyenko A V, Dry S, Cox H I, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin. Diabetes 2009;58:1604-15
83. Sinnett-Smith J, Kisfalvi K, Kui R, et al. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 2013;430:352-7
84. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008;359:1092-5
85. Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: B meta-Analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221-8
86. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: B meta-Analysis of randomised controlled trials. PLoS Med 2012;9:e1001204
87. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2012;13(2):73-84
88. Johansen O E, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: B pre-specified, prospective, and adjudicated meta-Analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3
89. Rosenstock J, Marx N, Kahn S E, et al. Rationale and design of the CAROLINA trial: Bn active comparator CARdiovascular Outcome study of the DPP-4 Inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk (Abstract). Diabetes 2011;60(SUPPL1):A303; Poster: 1103-P (71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24-28, 2011
90. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013; In press
91. Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol 2012;8:383-94
92. Cooper M VEM, Emser A, Patel S, Worle HJ. Efficacy and safety of linagliptin in patients with type 2 diabetes with or without renal impairment: Results from a global Phase 3 program. Diabetes 2011;60:Abstract 1068 P
93. McGill J B, Sloan L, Newman J, et al. Long-Term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: B 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36:237-44
94. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9
95. NICE. Type 2 diabetes: The management of type 2 diabetes: NICE Clinical Guideline 87: National Institute for Health and Clinical Excellence. 2009
96. Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: B systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-18
97. Paolisso G, Monami M, Marfella R, et al. Dipeptidyl peptidase-4 inhibitors in the elderly: More benefits or risks? Adv Ther 2012;29:218-33
98. Penfornis A, Bourdel-Marchasson I, Quere S, et al. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study. Diabetes Metab 2012;38:550-7
99. ClinicalTrials gov. Efficacy and safety of linagliptin in elderly patients with type 2 diabetes. 2011.Available from: Http://clinicaltrialsgov/ ct2/show/NCT01084005 [Accessed Jan 12 2011
100. Kosmalski M, Drozdowska A, Sliwinska A, et al. Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients. Adv Med Sci 2012;57:65-70